Pristinamycin

(BAN, rINN)
Synonyms: Pristinamicina; Pristinamycine; Pristinamycinum; RP-7293.
Cyrillic synonym: Пристинамицин.

💊 Chemical information

CAS — 270076-60-3.
ATC — J01FG01.
ATC Vet — QJ01FG01.

💊 Profile

Pristinamycin is a streptogramin antibacterial produced by the growth of Streptomyces pristina spiralis, with actions and uses similar to those of virginiamycin. It is given orally in the treatment of susceptible infections, particularly staphylococcal infections, in a dose of 2 to 4 g daily in divided doses. It has been available for many years as an oral antistaphylococcal drug, and also acts against streptococci. It is effective against strains showing resistance to erythromycin; resistance to pristinamycin is rare,2,3 although resistance in staphylococci has been reported in the past.4,5 It is effective against meticillin-resistant Staphylococcus aureus (MRSA)6,7 but its usefulness in severe infection is limited by its poor solubility, which prevents development of an intravenous formulation. Oral pristinamycin has been shown to be as effective as standard therapy with intravenous then oral penicillin in the treatment of erysipelas.8 Mixtures of water-soluble derivatives of pristinamycins I and II, such as quinupristin/dalfopristin, are in clinical use or under investigation.
1. Hamilton-Miller JMT. From foreign pharmacopoeias: ‘new’ antibiotics from old? J Antimicrob Chemother 1991; 27: 702–5
2. Weber P. Streptococcus pneumoniae: absence d’émergence de résistance à la pristinamycine. Pathol Biol (Paris) 2001; 49: 840–5
3. Leclercq R, et al. Activité in vitro de la pristinamycine vis-à-vis des staphylocoques isolés dans les hôpitaux français en 19992000. Pathol Biol (Paris) 2003; 51: 400–4
4. Loncle V, et al. Analysis of pristinamycin-resistant Staphylococcus epidermidis isolates responsible for an outbreak in a Parisian hospital. Antimicrob Agents Chemother 1993; 37: 2159–65
5. Allignet J, et al. Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics. Antimicrob Agents Chemother 1996; 40: 2523–8
6. Dancer SJ, et al. Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. J Antimicrob Chemother 2003; 51: 731–5
7. Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J Antimicrob Chemother 2005; 55: 1008–12
8. Bernard P, et al. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ 2002; 325: 864–6.

💊 Preparations

Proprietary Preparations

Fr.: Pyostacine; Israel: Pyostacine.
Published May 08, 2019.